nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—HTR2C—type 2 diabetes mellitus	0.21	0.57	CbGaD
Duloxetine—CYP1A2—type 2 diabetes mellitus	0.158	0.43	CbGaD
Duloxetine—HTR6—Bromocriptine—type 2 diabetes mellitus	0.0817	0.261	CbGbCtD
Duloxetine—HTR2C—Bromocriptine—type 2 diabetes mellitus	0.0475	0.152	CbGbCtD
Duloxetine—HTR2A—Bromocriptine—type 2 diabetes mellitus	0.0428	0.137	CbGbCtD
Duloxetine—CYP1A2—Rosiglitazone—type 2 diabetes mellitus	0.0232	0.0741	CbGbCtD
Duloxetine—CYP2D6—Pioglitazone—type 2 diabetes mellitus	0.0207	0.0662	CbGbCtD
Duloxetine—CYP2D6—Rosiglitazone—type 2 diabetes mellitus	0.0191	0.0611	CbGbCtD
Duloxetine—CYP1A2—Irbesartan—type 2 diabetes mellitus	0.0183	0.0584	CbGbCtD
Duloxetine—CYP1A2—Bromocriptine—type 2 diabetes mellitus	0.0173	0.0552	CbGbCtD
Duloxetine—CYP2D6—Nateglinide—type 2 diabetes mellitus	0.0157	0.0502	CbGbCtD
Duloxetine—CYP2D6—Irbesartan—type 2 diabetes mellitus	0.0151	0.0481	CbGbCtD
Duloxetine—CYP1A2—Losartan—type 2 diabetes mellitus	0.0118	0.0376	CbGbCtD
Duloxetine—NPY1R—nerve—type 2 diabetes mellitus	0.00433	0.128	CbGeAlD
Duloxetine—SLC6A2—sympathetic nervous system—type 2 diabetes mellitus	0.00389	0.115	CbGeAlD
Duloxetine—HTR2A—arteriole—type 2 diabetes mellitus	0.00367	0.108	CbGeAlD
Duloxetine—SLC6A2—autonomic nervous system—type 2 diabetes mellitus	0.00261	0.0772	CbGeAlD
Duloxetine—HTR2A—sympathetic nervous system—type 2 diabetes mellitus	0.00234	0.069	CbGeAlD
Duloxetine—SLC6A3—nerve—type 2 diabetes mellitus	0.00182	0.0538	CbGeAlD
Duloxetine—HTR2A—autonomic nervous system—type 2 diabetes mellitus	0.00157	0.0464	CbGeAlD
Duloxetine—NPY1R—pancreas—type 2 diabetes mellitus	0.00147	0.0435	CbGeAlD
Duloxetine—SLC6A2—nerve—type 2 diabetes mellitus	0.00147	0.0434	CbGeAlD
Duloxetine—HTR2A—hindlimb—type 2 diabetes mellitus	0.00145	0.0429	CbGeAlD
Duloxetine—NPY1R—cortex of kidney—type 2 diabetes mellitus	0.00145	0.0427	CbGeAlD
Duloxetine—NPY1R—adipose tissue—type 2 diabetes mellitus	0.00134	0.0395	CbGeAlD
Duloxetine—HTR2A—peripheral nervous system—type 2 diabetes mellitus	0.00113	0.0335	CbGeAlD
Duloxetine—NPY1R—liver—type 2 diabetes mellitus	0.000938	0.0277	CbGeAlD
Duloxetine—HTR2A—artery—type 2 diabetes mellitus	0.00089	0.0263	CbGeAlD
Duloxetine—HTR2A—nerve—type 2 diabetes mellitus	0.000883	0.0261	CbGeAlD
Duloxetine—HTR2A—endothelium—type 2 diabetes mellitus	0.000752	0.0222	CbGeAlD
Duloxetine—Naphazoline—ADRA2A—type 2 diabetes mellitus	0.000495	0.184	CrCbGaD
Duloxetine—Propranolol—ADRB3—type 2 diabetes mellitus	0.000411	0.152	CrCbGaD
Duloxetine—HTR2A—retina—type 2 diabetes mellitus	0.000366	0.0108	CbGeAlD
Duloxetine—Cinacalcet—CYP1A2—type 2 diabetes mellitus	0.000331	0.123	CrCbGaD
Duloxetine—HTR2A—cardiovascular system—type 2 diabetes mellitus	0.000309	0.00914	CbGeAlD
Duloxetine—HTR2A—kidney—type 2 diabetes mellitus	0.000303	0.00894	CbGeAlD
Duloxetine—Fluoxetine—HTR2C—type 2 diabetes mellitus	0.00028	0.104	CrCbGaD
Duloxetine—CYP2D6—kidney—type 2 diabetes mellitus	0.000276	0.00814	CbGeAlD
Duloxetine—CYP1A2—liver—type 2 diabetes mellitus	0.000245	0.00723	CbGeAlD
Duloxetine—Cinacalcet—CYP3A4—type 2 diabetes mellitus	0.000219	0.0814	CrCbGaD
Duloxetine—Fluoxetine—CYP1A2—type 2 diabetes mellitus	0.000212	0.0785	CrCbGaD
Duloxetine—HTR2A—liver—type 2 diabetes mellitus	0.000191	0.00565	CbGeAlD
Duloxetine—Atomoxetine—HTR2C—type 2 diabetes mellitus	0.00018	0.0668	CrCbGaD
Duloxetine—CYP2D6—liver—type 2 diabetes mellitus	0.000174	0.00515	CbGeAlD
Duloxetine—Fluoxetine—CYP3A4—type 2 diabetes mellitus	0.00014	0.052	CrCbGaD
Duloxetine—Propranolol—CYP1A2—type 2 diabetes mellitus	0.000129	0.0479	CrCbGaD
Duloxetine—Fluoxetine—ALB—type 2 diabetes mellitus	0.000122	0.0453	CrCbGaD
Duloxetine—Atomoxetine—CYP3A4—type 2 diabetes mellitus	9e-05	0.0334	CrCbGaD
Duloxetine—Propranolol—CYP3A4—type 2 diabetes mellitus	8.55e-05	0.0317	CrCbGaD
Duloxetine—Arthralgia—Irbesartan—type 2 diabetes mellitus	5.85e-05	0.000295	CcSEcCtD
Duloxetine—Myalgia—Irbesartan—type 2 diabetes mellitus	5.85e-05	0.000295	CcSEcCtD
Duloxetine—Shock—Metformin—type 2 diabetes mellitus	5.85e-05	0.000295	CcSEcCtD
Duloxetine—Insomnia—Orlistat—type 2 diabetes mellitus	5.83e-05	0.000295	CcSEcCtD
Duloxetine—Malaise—Losartan—type 2 diabetes mellitus	5.83e-05	0.000295	CcSEcCtD
Duloxetine—Anxiety—Irbesartan—type 2 diabetes mellitus	5.83e-05	0.000294	CcSEcCtD
Duloxetine—Hypersensitivity—Glyburide—type 2 diabetes mellitus	5.83e-05	0.000294	CcSEcCtD
Duloxetine—Nervous system disorder—Metformin—type 2 diabetes mellitus	5.83e-05	0.000294	CcSEcCtD
Duloxetine—Thrombocytopenia—Metformin—type 2 diabetes mellitus	5.82e-05	0.000294	CcSEcCtD
Duloxetine—Vertigo—Losartan—type 2 diabetes mellitus	5.81e-05	0.000293	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	5.81e-05	0.000293	CcSEcCtD
Duloxetine—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	5.81e-05	0.000293	CcSEcCtD
Duloxetine—Somnolence—Valsartan—type 2 diabetes mellitus	5.8e-05	0.000293	CcSEcCtD
Duloxetine—Syncope—Losartan—type 2 diabetes mellitus	5.8e-05	0.000293	CcSEcCtD
Duloxetine—Paraesthesia—Orlistat—type 2 diabetes mellitus	5.79e-05	0.000292	CcSEcCtD
Duloxetine—Leukopenia—Losartan—type 2 diabetes mellitus	5.79e-05	0.000292	CcSEcCtD
Duloxetine—Discomfort—Irbesartan—type 2 diabetes mellitus	5.78e-05	0.000292	CcSEcCtD
Duloxetine—Skin disorder—Metformin—type 2 diabetes mellitus	5.77e-05	0.000292	CcSEcCtD
Duloxetine—Immune system disorder—Ramipril—type 2 diabetes mellitus	5.75e-05	0.000291	CcSEcCtD
Duloxetine—Hyperhidrosis—Metformin—type 2 diabetes mellitus	5.74e-05	0.00029	CcSEcCtD
Duloxetine—Dyspepsia—Valsartan—type 2 diabetes mellitus	5.74e-05	0.00029	CcSEcCtD
Duloxetine—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	5.74e-05	0.00029	CcSEcCtD
Duloxetine—Dizziness—Bromocriptine—type 2 diabetes mellitus	5.72e-05	0.000289	CcSEcCtD
Duloxetine—Dry mouth—Irbesartan—type 2 diabetes mellitus	5.72e-05	0.000289	CcSEcCtD
Duloxetine—Palpitations—Losartan—type 2 diabetes mellitus	5.71e-05	0.000289	CcSEcCtD
Duloxetine—Nausea—Glimepiride—type 2 diabetes mellitus	5.7e-05	0.000288	CcSEcCtD
Duloxetine—Arrhythmia—Ramipril—type 2 diabetes mellitus	5.69e-05	0.000287	CcSEcCtD
Duloxetine—Loss of consciousness—Losartan—type 2 diabetes mellitus	5.68e-05	0.000287	CcSEcCtD
Duloxetine—Nausea—Sitagliptin—type 2 diabetes mellitus	5.68e-05	0.000287	CcSEcCtD
Duloxetine—Dyspepsia—Orlistat—type 2 diabetes mellitus	5.68e-05	0.000287	CcSEcCtD
Duloxetine—Asthenia—Glyburide—type 2 diabetes mellitus	5.67e-05	0.000287	CcSEcCtD
Duloxetine—Decreased appetite—Valsartan—type 2 diabetes mellitus	5.67e-05	0.000287	CcSEcCtD
Duloxetine—Anorexia—Metformin—type 2 diabetes mellitus	5.66e-05	0.000286	CcSEcCtD
Duloxetine—Cough—Losartan—type 2 diabetes mellitus	5.64e-05	0.000285	CcSEcCtD
Duloxetine—Urticaria—Gliclazide—type 2 diabetes mellitus	5.64e-05	0.000285	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	5.63e-05	0.000285	CcSEcCtD
Duloxetine—Alopecia—Ramipril—type 2 diabetes mellitus	5.63e-05	0.000284	CcSEcCtD
Duloxetine—Fatigue—Valsartan—type 2 diabetes mellitus	5.63e-05	0.000284	CcSEcCtD
Duloxetine—Body temperature increased—Gliclazide—type 2 diabetes mellitus	5.61e-05	0.000284	CcSEcCtD
Duloxetine—Abdominal pain—Gliclazide—type 2 diabetes mellitus	5.61e-05	0.000284	CcSEcCtD
Duloxetine—Oedema—Irbesartan—type 2 diabetes mellitus	5.61e-05	0.000283	CcSEcCtD
Duloxetine—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	5.61e-05	0.000283	CcSEcCtD
Duloxetine—Decreased appetite—Orlistat—type 2 diabetes mellitus	5.6e-05	0.000283	CcSEcCtD
Duloxetine—Pruritus—Glyburide—type 2 diabetes mellitus	5.6e-05	0.000283	CcSEcCtD
Duloxetine—Mental disorder—Ramipril—type 2 diabetes mellitus	5.58e-05	0.000282	CcSEcCtD
Duloxetine—Constipation—Valsartan—type 2 diabetes mellitus	5.58e-05	0.000282	CcSEcCtD
Duloxetine—Infection—Irbesartan—type 2 diabetes mellitus	5.57e-05	0.000281	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	5.57e-05	0.000281	CcSEcCtD
Duloxetine—Fatigue—Orlistat—type 2 diabetes mellitus	5.56e-05	0.000281	CcSEcCtD
Duloxetine—Malnutrition—Ramipril—type 2 diabetes mellitus	5.54e-05	0.00028	CcSEcCtD
Duloxetine—Erythema—Ramipril—type 2 diabetes mellitus	5.54e-05	0.00028	CcSEcCtD
Duloxetine—Shock—Irbesartan—type 2 diabetes mellitus	5.52e-05	0.000279	CcSEcCtD
Duloxetine—Pain—Orlistat—type 2 diabetes mellitus	5.51e-05	0.000279	CcSEcCtD
Duloxetine—Myalgia—Losartan—type 2 diabetes mellitus	5.5e-05	0.000278	CcSEcCtD
Duloxetine—Arthralgia—Losartan—type 2 diabetes mellitus	5.5e-05	0.000278	CcSEcCtD
Duloxetine—Chest pain—Losartan—type 2 diabetes mellitus	5.5e-05	0.000278	CcSEcCtD
Duloxetine—Vomiting—Bromocriptine—type 2 diabetes mellitus	5.5e-05	0.000278	CcSEcCtD
Duloxetine—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	5.5e-05	0.000278	CcSEcCtD
Duloxetine—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	5.49e-05	0.000277	CcSEcCtD
Duloxetine—Anxiety—Losartan—type 2 diabetes mellitus	5.49e-05	0.000277	CcSEcCtD
Duloxetine—Tachycardia—Irbesartan—type 2 diabetes mellitus	5.47e-05	0.000276	CcSEcCtD
Duloxetine—Rash—Bromocriptine—type 2 diabetes mellitus	5.45e-05	0.000276	CcSEcCtD
Duloxetine—Dermatitis—Bromocriptine—type 2 diabetes mellitus	5.45e-05	0.000275	CcSEcCtD
Duloxetine—Skin disorder—Irbesartan—type 2 diabetes mellitus	5.45e-05	0.000275	CcSEcCtD
Duloxetine—Tension—Ramipril—type 2 diabetes mellitus	5.44e-05	0.000275	CcSEcCtD
Duloxetine—Discomfort—Losartan—type 2 diabetes mellitus	5.44e-05	0.000275	CcSEcCtD
Duloxetine—Dysgeusia—Ramipril—type 2 diabetes mellitus	5.43e-05	0.000274	CcSEcCtD
Duloxetine—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	5.42e-05	0.000274	CcSEcCtD
Duloxetine—Headache—Bromocriptine—type 2 diabetes mellitus	5.42e-05	0.000274	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	5.41e-05	0.000273	CcSEcCtD
Duloxetine—Diarrhoea—Glyburide—type 2 diabetes mellitus	5.41e-05	0.000273	CcSEcCtD
Duloxetine—Nervousness—Ramipril—type 2 diabetes mellitus	5.38e-05	0.000272	CcSEcCtD
Duloxetine—Dry mouth—Losartan—type 2 diabetes mellitus	5.38e-05	0.000272	CcSEcCtD
Duloxetine—Anorexia—Irbesartan—type 2 diabetes mellitus	5.34e-05	0.00027	CcSEcCtD
Duloxetine—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	5.34e-05	0.00027	CcSEcCtD
Duloxetine—Paraesthesia—Metformin—type 2 diabetes mellitus	5.34e-05	0.00027	CcSEcCtD
Duloxetine—Muscle spasms—Ramipril—type 2 diabetes mellitus	5.33e-05	0.000269	CcSEcCtD
Duloxetine—Confusional state—Losartan—type 2 diabetes mellitus	5.32e-05	0.000269	CcSEcCtD
Duloxetine—Feeling abnormal—Orlistat—type 2 diabetes mellitus	5.31e-05	0.000268	CcSEcCtD
Duloxetine—Somnolence—Metformin—type 2 diabetes mellitus	5.28e-05	0.000267	CcSEcCtD
Duloxetine—Anaphylactic shock—Losartan—type 2 diabetes mellitus	5.28e-05	0.000267	CcSEcCtD
Duloxetine—Oedema—Losartan—type 2 diabetes mellitus	5.28e-05	0.000267	CcSEcCtD
Duloxetine—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	5.27e-05	0.000266	CcSEcCtD
Duloxetine—Infection—Losartan—type 2 diabetes mellitus	5.24e-05	0.000265	CcSEcCtD
Duloxetine—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	5.23e-05	0.000264	CcSEcCtD
Duloxetine—Dyspepsia—Metformin—type 2 diabetes mellitus	5.23e-05	0.000264	CcSEcCtD
Duloxetine—Tremor—Ramipril—type 2 diabetes mellitus	5.19e-05	0.000262	CcSEcCtD
Duloxetine—Shock—Losartan—type 2 diabetes mellitus	5.19e-05	0.000262	CcSEcCtD
Duloxetine—Urticaria—Valsartan—type 2 diabetes mellitus	5.18e-05	0.000262	CcSEcCtD
Duloxetine—Nervous system disorder—Losartan—type 2 diabetes mellitus	5.17e-05	0.000261	CcSEcCtD
Duloxetine—Thrombocytopenia—Losartan—type 2 diabetes mellitus	5.17e-05	0.000261	CcSEcCtD
Duloxetine—Decreased appetite—Metformin—type 2 diabetes mellitus	5.17e-05	0.000261	CcSEcCtD
Duloxetine—Abdominal pain—Valsartan—type 2 diabetes mellitus	5.16e-05	0.000261	CcSEcCtD
Duloxetine—Tachycardia—Losartan—type 2 diabetes mellitus	5.15e-05	0.00026	CcSEcCtD
Duloxetine—Ill-defined disorder—Ramipril—type 2 diabetes mellitus	5.14e-05	0.00026	CcSEcCtD
Duloxetine—Nausea—Bromocriptine—type 2 diabetes mellitus	5.14e-05	0.00026	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	5.13e-05	0.000259	CcSEcCtD
Duloxetine—Fatigue—Metformin—type 2 diabetes mellitus	5.12e-05	0.000259	CcSEcCtD
Duloxetine—Urticaria—Orlistat—type 2 diabetes mellitus	5.12e-05	0.000259	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	5.11e-05	0.000258	CcSEcCtD
Duloxetine—Hyperhidrosis—Losartan—type 2 diabetes mellitus	5.1e-05	0.000258	CcSEcCtD
Duloxetine—Abdominal pain—Orlistat—type 2 diabetes mellitus	5.1e-05	0.000257	CcSEcCtD
Duloxetine—Body temperature increased—Orlistat—type 2 diabetes mellitus	5.1e-05	0.000257	CcSEcCtD
Duloxetine—Asthenia—Gliclazide—type 2 diabetes mellitus	5.1e-05	0.000257	CcSEcCtD
Duloxetine—Agitation—Ramipril—type 2 diabetes mellitus	5.09e-05	0.000257	CcSEcCtD
Duloxetine—Constipation—Metformin—type 2 diabetes mellitus	5.08e-05	0.000257	CcSEcCtD
Duloxetine—Angioedema—Ramipril—type 2 diabetes mellitus	5.07e-05	0.000256	CcSEcCtD
Duloxetine—Paraesthesia—Irbesartan—type 2 diabetes mellitus	5.03e-05	0.000254	CcSEcCtD
Duloxetine—Anorexia—Losartan—type 2 diabetes mellitus	5.03e-05	0.000254	CcSEcCtD
Duloxetine—Vomiting—Glyburide—type 2 diabetes mellitus	5.03e-05	0.000254	CcSEcCtD
Duloxetine—Pruritus—Gliclazide—type 2 diabetes mellitus	5.02e-05	0.000254	CcSEcCtD
Duloxetine—Malaise—Ramipril—type 2 diabetes mellitus	5e-05	0.000253	CcSEcCtD
Duloxetine—Rash—Glyburide—type 2 diabetes mellitus	4.99e-05	0.000252	CcSEcCtD
Duloxetine—Somnolence—Irbesartan—type 2 diabetes mellitus	4.98e-05	0.000252	CcSEcCtD
Duloxetine—Dermatitis—Glyburide—type 2 diabetes mellitus	4.98e-05	0.000252	CcSEcCtD
Duloxetine—Vertigo—Ramipril—type 2 diabetes mellitus	4.98e-05	0.000252	CcSEcCtD
Duloxetine—Syncope—Ramipril—type 2 diabetes mellitus	4.97e-05	0.000251	CcSEcCtD
Duloxetine—Leukopenia—Ramipril—type 2 diabetes mellitus	4.96e-05	0.000251	CcSEcCtD
Duloxetine—Headache—Glyburide—type 2 diabetes mellitus	4.95e-05	0.00025	CcSEcCtD
Duloxetine—Dyspepsia—Irbesartan—type 2 diabetes mellitus	4.94e-05	0.000249	CcSEcCtD
Duloxetine—Palpitations—Ramipril—type 2 diabetes mellitus	4.9e-05	0.000247	CcSEcCtD
Duloxetine—Feeling abnormal—Metformin—type 2 diabetes mellitus	4.9e-05	0.000247	CcSEcCtD
Duloxetine—Decreased appetite—Irbesartan—type 2 diabetes mellitus	4.87e-05	0.000246	CcSEcCtD
Duloxetine—Loss of consciousness—Ramipril—type 2 diabetes mellitus	4.87e-05	0.000246	CcSEcCtD
Duloxetine—Diarrhoea—Gliclazide—type 2 diabetes mellitus	4.86e-05	0.000245	CcSEcCtD
Duloxetine—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	4.86e-05	0.000245	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	4.84e-05	0.000245	CcSEcCtD
Duloxetine—Cough—Ramipril—type 2 diabetes mellitus	4.84e-05	0.000244	CcSEcCtD
Duloxetine—Fatigue—Irbesartan—type 2 diabetes mellitus	4.83e-05	0.000244	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	4.81e-05	0.000243	CcSEcCtD
Duloxetine—Hypersensitivity—Valsartan—type 2 diabetes mellitus	4.81e-05	0.000243	CcSEcCtD
Duloxetine—Convulsion—Ramipril—type 2 diabetes mellitus	4.8e-05	0.000243	CcSEcCtD
Duloxetine—Pain—Irbesartan—type 2 diabetes mellitus	4.79e-05	0.000242	CcSEcCtD
Duloxetine—Constipation—Irbesartan—type 2 diabetes mellitus	4.79e-05	0.000242	CcSEcCtD
Duloxetine—Insomnia—Losartan—type 2 diabetes mellitus	4.77e-05	0.000241	CcSEcCtD
Duloxetine—Hypersensitivity—Orlistat—type 2 diabetes mellitus	4.75e-05	0.00024	CcSEcCtD
Duloxetine—Paraesthesia—Losartan—type 2 diabetes mellitus	4.74e-05	0.000239	CcSEcCtD
Duloxetine—Urticaria—Metformin—type 2 diabetes mellitus	4.72e-05	0.000238	CcSEcCtD
Duloxetine—Myalgia—Ramipril—type 2 diabetes mellitus	4.72e-05	0.000238	CcSEcCtD
Duloxetine—Arthralgia—Ramipril—type 2 diabetes mellitus	4.72e-05	0.000238	CcSEcCtD
Duloxetine—Chest pain—Ramipril—type 2 diabetes mellitus	4.72e-05	0.000238	CcSEcCtD
Duloxetine—Anxiety—Ramipril—type 2 diabetes mellitus	4.7e-05	0.000238	CcSEcCtD
Duloxetine—Nausea—Glyburide—type 2 diabetes mellitus	4.7e-05	0.000237	CcSEcCtD
Duloxetine—Abdominal pain—Metformin—type 2 diabetes mellitus	4.7e-05	0.000237	CcSEcCtD
Duloxetine—Dizziness—Gliclazide—type 2 diabetes mellitus	4.7e-05	0.000237	CcSEcCtD
Duloxetine—Somnolence—Losartan—type 2 diabetes mellitus	4.69e-05	0.000237	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	4.69e-05	0.000237	CcSEcCtD
Duloxetine—Asthenia—Valsartan—type 2 diabetes mellitus	4.68e-05	0.000236	CcSEcCtD
Duloxetine—Discomfort—Ramipril—type 2 diabetes mellitus	4.66e-05	0.000236	CcSEcCtD
Duloxetine—Dyspepsia—Losartan—type 2 diabetes mellitus	4.65e-05	0.000235	CcSEcCtD
Duloxetine—Asthenia—Orlistat—type 2 diabetes mellitus	4.63e-05	0.000234	CcSEcCtD
Duloxetine—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	4.62e-05	0.000233	CcSEcCtD
Duloxetine—Pruritus—Valsartan—type 2 diabetes mellitus	4.62e-05	0.000233	CcSEcCtD
Duloxetine—Dry mouth—Ramipril—type 2 diabetes mellitus	4.62e-05	0.000233	CcSEcCtD
Duloxetine—Decreased appetite—Losartan—type 2 diabetes mellitus	4.59e-05	0.000232	CcSEcCtD
Duloxetine—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	4.59e-05	0.000232	CcSEcCtD
Duloxetine—Confusional state—Ramipril—type 2 diabetes mellitus	4.56e-05	0.00023	CcSEcCtD
Duloxetine—Pruritus—Orlistat—type 2 diabetes mellitus	4.56e-05	0.00023	CcSEcCtD
Duloxetine—Fatigue—Losartan—type 2 diabetes mellitus	4.55e-05	0.00023	CcSEcCtD
Duloxetine—Oedema—Ramipril—type 2 diabetes mellitus	4.52e-05	0.000229	CcSEcCtD
Duloxetine—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	4.52e-05	0.000229	CcSEcCtD
Duloxetine—Vomiting—Gliclazide—type 2 diabetes mellitus	4.52e-05	0.000228	CcSEcCtD
Duloxetine—Pain—Losartan—type 2 diabetes mellitus	4.51e-05	0.000228	CcSEcCtD
Duloxetine—Constipation—Losartan—type 2 diabetes mellitus	4.51e-05	0.000228	CcSEcCtD
Duloxetine—Rash—Gliclazide—type 2 diabetes mellitus	4.48e-05	0.000226	CcSEcCtD
Duloxetine—Dermatitis—Gliclazide—type 2 diabetes mellitus	4.47e-05	0.000226	CcSEcCtD
Duloxetine—Diarrhoea—Valsartan—type 2 diabetes mellitus	4.46e-05	0.000226	CcSEcCtD
Duloxetine—Urticaria—Irbesartan—type 2 diabetes mellitus	4.45e-05	0.000225	CcSEcCtD
Duloxetine—Shock—Ramipril—type 2 diabetes mellitus	4.45e-05	0.000225	CcSEcCtD
Duloxetine—Headache—Gliclazide—type 2 diabetes mellitus	4.45e-05	0.000225	CcSEcCtD
Duloxetine—Nervous system disorder—Ramipril—type 2 diabetes mellitus	4.44e-05	0.000224	CcSEcCtD
Duloxetine—Body temperature increased—Irbesartan—type 2 diabetes mellitus	4.43e-05	0.000224	CcSEcCtD
Duloxetine—Abdominal pain—Irbesartan—type 2 diabetes mellitus	4.43e-05	0.000224	CcSEcCtD
Duloxetine—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	4.43e-05	0.000224	CcSEcCtD
Duloxetine—Tachycardia—Ramipril—type 2 diabetes mellitus	4.42e-05	0.000223	CcSEcCtD
Duloxetine—Diarrhoea—Orlistat—type 2 diabetes mellitus	4.41e-05	0.000223	CcSEcCtD
Duloxetine—Skin disorder—Ramipril—type 2 diabetes mellitus	4.39e-05	0.000222	CcSEcCtD
Duloxetine—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	4.37e-05	0.000221	CcSEcCtD
Duloxetine—Feeling abnormal—Losartan—type 2 diabetes mellitus	4.35e-05	0.00022	CcSEcCtD
Duloxetine—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	4.32e-05	0.000218	CcSEcCtD
Duloxetine—Dizziness—Valsartan—type 2 diabetes mellitus	4.31e-05	0.000218	CcSEcCtD
Duloxetine—Anorexia—Ramipril—type 2 diabetes mellitus	4.31e-05	0.000218	CcSEcCtD
Duloxetine—Dizziness—Orlistat—type 2 diabetes mellitus	4.26e-05	0.000215	CcSEcCtD
Duloxetine—Asthenia—Metformin—type 2 diabetes mellitus	4.26e-05	0.000215	CcSEcCtD
Duloxetine—Nausea—Gliclazide—type 2 diabetes mellitus	4.22e-05	0.000213	CcSEcCtD
Duloxetine—Pruritus—Metformin—type 2 diabetes mellitus	4.2e-05	0.000212	CcSEcCtD
Duloxetine—Urticaria—Losartan—type 2 diabetes mellitus	4.19e-05	0.000212	CcSEcCtD
Duloxetine—Abdominal pain—Losartan—type 2 diabetes mellitus	4.17e-05	0.000211	CcSEcCtD
Duloxetine—Body temperature increased—Losartan—type 2 diabetes mellitus	4.17e-05	0.000211	CcSEcCtD
Duloxetine—Vomiting—Valsartan—type 2 diabetes mellitus	4.15e-05	0.00021	CcSEcCtD
Duloxetine—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	4.13e-05	0.000209	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	4.12e-05	0.000208	CcSEcCtD
Duloxetine—Rash—Valsartan—type 2 diabetes mellitus	4.11e-05	0.000208	CcSEcCtD
Duloxetine—Dermatitis—Valsartan—type 2 diabetes mellitus	4.11e-05	0.000208	CcSEcCtD
Duloxetine—Vomiting—Orlistat—type 2 diabetes mellitus	4.1e-05	0.000207	CcSEcCtD
Duloxetine—Insomnia—Ramipril—type 2 diabetes mellitus	4.09e-05	0.000207	CcSEcCtD
Duloxetine—Headache—Valsartan—type 2 diabetes mellitus	4.09e-05	0.000206	CcSEcCtD
Duloxetine—Diarrhoea—Metformin—type 2 diabetes mellitus	4.07e-05	0.000205	CcSEcCtD
Duloxetine—Rash—Orlistat—type 2 diabetes mellitus	4.07e-05	0.000205	CcSEcCtD
Duloxetine—Paraesthesia—Ramipril—type 2 diabetes mellitus	4.06e-05	0.000205	CcSEcCtD
Duloxetine—Dermatitis—Orlistat—type 2 diabetes mellitus	4.06e-05	0.000205	CcSEcCtD
Duloxetine—Headache—Orlistat—type 2 diabetes mellitus	4.04e-05	0.000204	CcSEcCtD
Duloxetine—Asthenia—Irbesartan—type 2 diabetes mellitus	4.02e-05	0.000203	CcSEcCtD
Duloxetine—Somnolence—Ramipril—type 2 diabetes mellitus	4.02e-05	0.000203	CcSEcCtD
Duloxetine—Dyspepsia—Ramipril—type 2 diabetes mellitus	3.98e-05	0.000201	CcSEcCtD
Duloxetine—Pruritus—Irbesartan—type 2 diabetes mellitus	3.97e-05	0.0002	CcSEcCtD
Duloxetine—Decreased appetite—Ramipril—type 2 diabetes mellitus	3.93e-05	0.000199	CcSEcCtD
Duloxetine—Dizziness—Metformin—type 2 diabetes mellitus	3.93e-05	0.000198	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	3.91e-05	0.000197	CcSEcCtD
Duloxetine—Fatigue—Ramipril—type 2 diabetes mellitus	3.9e-05	0.000197	CcSEcCtD
Duloxetine—Hypersensitivity—Losartan—type 2 diabetes mellitus	3.89e-05	0.000196	CcSEcCtD
Duloxetine—Nausea—Valsartan—type 2 diabetes mellitus	3.88e-05	0.000196	CcSEcCtD
Duloxetine—Constipation—Ramipril—type 2 diabetes mellitus	3.87e-05	0.000195	CcSEcCtD
Duloxetine—Diarrhoea—Irbesartan—type 2 diabetes mellitus	3.84e-05	0.000194	CcSEcCtD
Duloxetine—Nausea—Orlistat—type 2 diabetes mellitus	3.83e-05	0.000193	CcSEcCtD
Duloxetine—Asthenia—Losartan—type 2 diabetes mellitus	3.79e-05	0.000191	CcSEcCtD
Duloxetine—Vomiting—Metformin—type 2 diabetes mellitus	3.78e-05	0.000191	CcSEcCtD
Duloxetine—Rash—Metformin—type 2 diabetes mellitus	3.75e-05	0.000189	CcSEcCtD
Duloxetine—Dermatitis—Metformin—type 2 diabetes mellitus	3.74e-05	0.000189	CcSEcCtD
Duloxetine—Pruritus—Losartan—type 2 diabetes mellitus	3.73e-05	0.000189	CcSEcCtD
Duloxetine—Feeling abnormal—Ramipril—type 2 diabetes mellitus	3.73e-05	0.000188	CcSEcCtD
Duloxetine—Headache—Metformin—type 2 diabetes mellitus	3.72e-05	0.000188	CcSEcCtD
Duloxetine—Dizziness—Irbesartan—type 2 diabetes mellitus	3.71e-05	0.000187	CcSEcCtD
Duloxetine—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	3.7e-05	0.000187	CcSEcCtD
Duloxetine—Diarrhoea—Losartan—type 2 diabetes mellitus	3.61e-05	0.000182	CcSEcCtD
Duloxetine—Urticaria—Ramipril—type 2 diabetes mellitus	3.59e-05	0.000182	CcSEcCtD
Duloxetine—Body temperature increased—Ramipril—type 2 diabetes mellitus	3.58e-05	0.000181	CcSEcCtD
Duloxetine—Abdominal pain—Ramipril—type 2 diabetes mellitus	3.58e-05	0.000181	CcSEcCtD
Duloxetine—Vomiting—Irbesartan—type 2 diabetes mellitus	3.57e-05	0.00018	CcSEcCtD
Duloxetine—Rash—Irbesartan—type 2 diabetes mellitus	3.54e-05	0.000179	CcSEcCtD
Duloxetine—Dermatitis—Irbesartan—type 2 diabetes mellitus	3.53e-05	0.000178	CcSEcCtD
Duloxetine—Nausea—Metformin—type 2 diabetes mellitus	3.53e-05	0.000178	CcSEcCtD
Duloxetine—Headache—Irbesartan—type 2 diabetes mellitus	3.51e-05	0.000177	CcSEcCtD
Duloxetine—Dizziness—Losartan—type 2 diabetes mellitus	3.49e-05	0.000176	CcSEcCtD
Duloxetine—Vomiting—Losartan—type 2 diabetes mellitus	3.36e-05	0.000169	CcSEcCtD
Duloxetine—Hypersensitivity—Ramipril—type 2 diabetes mellitus	3.33e-05	0.000168	CcSEcCtD
Duloxetine—Nausea—Irbesartan—type 2 diabetes mellitus	3.33e-05	0.000168	CcSEcCtD
Duloxetine—Rash—Losartan—type 2 diabetes mellitus	3.33e-05	0.000168	CcSEcCtD
Duloxetine—Dermatitis—Losartan—type 2 diabetes mellitus	3.32e-05	0.000168	CcSEcCtD
Duloxetine—Headache—Losartan—type 2 diabetes mellitus	3.31e-05	0.000167	CcSEcCtD
Duloxetine—Asthenia—Ramipril—type 2 diabetes mellitus	3.25e-05	0.000164	CcSEcCtD
Duloxetine—Pruritus—Ramipril—type 2 diabetes mellitus	3.2e-05	0.000162	CcSEcCtD
Duloxetine—Nausea—Losartan—type 2 diabetes mellitus	3.13e-05	0.000158	CcSEcCtD
Duloxetine—Diarrhoea—Ramipril—type 2 diabetes mellitus	3.1e-05	0.000156	CcSEcCtD
Duloxetine—Dizziness—Ramipril—type 2 diabetes mellitus	2.99e-05	0.000151	CcSEcCtD
Duloxetine—Vomiting—Ramipril—type 2 diabetes mellitus	2.88e-05	0.000145	CcSEcCtD
Duloxetine—Rash—Ramipril—type 2 diabetes mellitus	2.85e-05	0.000144	CcSEcCtD
Duloxetine—Dermatitis—Ramipril—type 2 diabetes mellitus	2.85e-05	0.000144	CcSEcCtD
Duloxetine—Headache—Ramipril—type 2 diabetes mellitus	2.83e-05	0.000143	CcSEcCtD
Duloxetine—Nausea—Ramipril—type 2 diabetes mellitus	2.69e-05	0.000136	CcSEcCtD
Duloxetine—HTR2A—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	6.88e-06	8.19e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GHRL—type 2 diabetes mellitus	6.85e-06	8.16e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PLAT—type 2 diabetes mellitus	6.85e-06	8.16e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CALCA—type 2 diabetes mellitus	6.77e-06	8.06e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CCL2—type 2 diabetes mellitus	6.76e-06	8.04e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PCK1—type 2 diabetes mellitus	6.74e-06	8.02e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—AKT2—type 2 diabetes mellitus	6.64e-06	7.9e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—LPL—type 2 diabetes mellitus	6.63e-06	7.9e-05	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	6.63e-06	7.9e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HIF1A—type 2 diabetes mellitus	6.61e-06	7.86e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IRS2—type 2 diabetes mellitus	6.59e-06	7.84e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	6.58e-06	7.84e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—AGT—type 2 diabetes mellitus	6.58e-06	7.84e-05	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—IL6—type 2 diabetes mellitus	6.53e-06	7.77e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—type 2 diabetes mellitus	6.47e-06	7.71e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CALM1—type 2 diabetes mellitus	6.47e-06	7.7e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—LEP—type 2 diabetes mellitus	6.45e-06	7.68e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—APOE—type 2 diabetes mellitus	6.45e-06	7.68e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GLP1R—type 2 diabetes mellitus	6.41e-06	7.63e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	6.38e-06	7.59e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—APOA1—type 2 diabetes mellitus	6.37e-06	7.59e-05	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	6.35e-06	7.56e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—HK1—type 2 diabetes mellitus	6.31e-06	7.51e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CD36—type 2 diabetes mellitus	6.3e-06	7.51e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	6.28e-06	7.48e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PTPN1—type 2 diabetes mellitus	6.27e-06	7.46e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GCG—type 2 diabetes mellitus	6.27e-06	7.46e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—GNB3—type 2 diabetes mellitus	6.22e-06	7.41e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	6.17e-06	7.34e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	6.15e-06	7.32e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AVP—type 2 diabetes mellitus	6.14e-06	7.31e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MMP3—type 2 diabetes mellitus	6.14e-06	7.31e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IGF2—type 2 diabetes mellitus	6.11e-06	7.28e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—KCNJ11—type 2 diabetes mellitus	6.1e-06	7.26e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—LPA—type 2 diabetes mellitus	6.1e-06	7.26e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GCKR—type 2 diabetes mellitus	6.1e-06	7.26e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—HSD3B2—type 2 diabetes mellitus	6.1e-06	7.26e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	6.09e-06	7.24e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PRKCB—type 2 diabetes mellitus	6.08e-06	7.24e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	6.02e-06	7.17e-05	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.02e-06	7.17e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SLC2A2—type 2 diabetes mellitus	5.99e-06	7.13e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—APOB—type 2 diabetes mellitus	5.93e-06	7.06e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IGF1R—type 2 diabetes mellitus	5.91e-06	7.03e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CCL2—type 2 diabetes mellitus	5.87e-06	6.99e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CPT1A—type 2 diabetes mellitus	5.87e-06	6.98e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—MTR—type 2 diabetes mellitus	5.87e-06	6.98e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—type 2 diabetes mellitus	5.86e-06	6.98e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ALDOB—type 2 diabetes mellitus	5.84e-06	6.96e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—EDN1—type 2 diabetes mellitus	5.84e-06	6.95e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—AKT2—type 2 diabetes mellitus	5.76e-06	6.86e-05	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	5.76e-06	6.86e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IRS1—type 2 diabetes mellitus	5.75e-06	6.85e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NAMPT—type 2 diabetes mellitus	5.75e-06	6.85e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—LIPC—type 2 diabetes mellitus	5.72e-06	6.8e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—HBA1—type 2 diabetes mellitus	5.72e-06	6.8e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GCK—type 2 diabetes mellitus	5.72e-06	6.8e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP11A1—type 2 diabetes mellitus	5.68e-06	6.76e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—AGT—type 2 diabetes mellitus	5.68e-06	6.76e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—LPL—type 2 diabetes mellitus	5.67e-06	6.74e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SLC9A1—type 2 diabetes mellitus	5.58e-06	6.64e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—type 2 diabetes mellitus	5.56e-06	6.62e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ADCY5—type 2 diabetes mellitus	5.55e-06	6.6e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CETP—type 2 diabetes mellitus	5.51e-06	6.56e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—INS—type 2 diabetes mellitus	5.51e-06	6.56e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—type 2 diabetes mellitus	5.5e-06	6.55e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	5.45e-06	6.49e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GLP1R—type 2 diabetes mellitus	5.43e-06	6.47e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCL2—type 2 diabetes mellitus	5.42e-06	6.45e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GNB3—type 2 diabetes mellitus	5.4e-06	6.43e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MMP3—type 2 diabetes mellitus	5.33e-06	6.35e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AVP—type 2 diabetes mellitus	5.33e-06	6.35e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IGF1—type 2 diabetes mellitus	5.33e-06	6.34e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—AKT2—type 2 diabetes mellitus	5.32e-06	6.34e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	5.32e-06	6.33e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IGF2—type 2 diabetes mellitus	5.31e-06	6.32e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—EGFR—type 2 diabetes mellitus	5.3e-06	6.31e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	5.28e-06	6.29e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	5.23e-06	6.23e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCR5—type 2 diabetes mellitus	5.22e-06	6.21e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—APOB—type 2 diabetes mellitus	5.15e-06	6.13e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IGF1R—type 2 diabetes mellitus	5.13e-06	6.11e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PSMD6—type 2 diabetes mellitus	5.13e-06	6.1e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SREBF1—type 2 diabetes mellitus	5.13e-06	6.1e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SNAP25—type 2 diabetes mellitus	5.13e-06	6.1e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—C3—type 2 diabetes mellitus	5.1e-06	6.07e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SLC2A2—type 2 diabetes mellitus	5.07e-06	6.04e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—EDN1—type 2 diabetes mellitus	5.07e-06	6.04e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	5.06e-06	6.02e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CTGF—type 2 diabetes mellitus	5.03e-06	5.99e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—HMGCR—type 2 diabetes mellitus	4.99e-06	5.94e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—MTR—type 2 diabetes mellitus	4.97e-06	5.92e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CPT1A—type 2 diabetes mellitus	4.97e-06	5.92e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—LPL—type 2 diabetes mellitus	4.92e-06	5.86e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ADRA2A—type 2 diabetes mellitus	4.88e-06	5.81e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NAMPT—type 2 diabetes mellitus	4.87e-06	5.8e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HIF1A—type 2 diabetes mellitus	4.86e-06	5.79e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IRS2—type 2 diabetes mellitus	4.85e-06	5.78e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AGT—type 2 diabetes mellitus	4.85e-06	5.77e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—type 2 diabetes mellitus	4.84e-06	5.77e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—HBA1—type 2 diabetes mellitus	4.84e-06	5.76e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—LIPC—type 2 diabetes mellitus	4.84e-06	5.76e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GCK—type 2 diabetes mellitus	4.84e-06	5.76e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	4.83e-06	5.75e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NOS3—type 2 diabetes mellitus	4.83e-06	5.75e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ADCY5—type 2 diabetes mellitus	4.82e-06	5.73e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP11A1—type 2 diabetes mellitus	4.81e-06	5.73e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CALM1—type 2 diabetes mellitus	4.77e-06	5.67e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—APOE—type 2 diabetes mellitus	4.75e-06	5.65e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—LEP—type 2 diabetes mellitus	4.75e-06	5.65e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SLC9A1—type 2 diabetes mellitus	4.73e-06	5.63e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—APOA1—type 2 diabetes mellitus	4.69e-06	5.59e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP2E1—type 2 diabetes mellitus	4.69e-06	5.58e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CETP—type 2 diabetes mellitus	4.67e-06	5.56e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP1A2—type 2 diabetes mellitus	4.64e-06	5.52e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SLC2A1—type 2 diabetes mellitus	4.64e-06	5.52e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	4.62e-06	5.5e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—RELA—type 2 diabetes mellitus	4.55e-06	5.41e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCR5—type 2 diabetes mellitus	4.53e-06	5.4e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP3A4—type 2 diabetes mellitus	4.52e-06	5.38e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PRKCB—type 2 diabetes mellitus	4.48e-06	5.33e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GCG—type 2 diabetes mellitus	4.44e-06	5.29e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SLC2A4—type 2 diabetes mellitus	4.44e-06	5.29e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—C3—type 2 diabetes mellitus	4.43e-06	5.27e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—type 2 diabetes mellitus	4.36e-06	5.19e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PSMD6—type 2 diabetes mellitus	4.34e-06	5.17e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SREBF1—type 2 diabetes mellitus	4.34e-06	5.17e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SNAP25—type 2 diabetes mellitus	4.34e-06	5.17e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CTGF—type 2 diabetes mellitus	4.26e-06	5.07e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IRS1—type 2 diabetes mellitus	4.24e-06	5.04e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—HMGCR—type 2 diabetes mellitus	4.22e-06	5.03e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	4.22e-06	5.03e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IRS2—type 2 diabetes mellitus	4.21e-06	5.02e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AGT—type 2 diabetes mellitus	4.21e-06	5.01e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—type 2 diabetes mellitus	4.17e-06	4.96e-05	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	4.14e-06	4.93e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CALM1—type 2 diabetes mellitus	4.14e-06	4.93e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ADRA2A—type 2 diabetes mellitus	4.13e-06	4.92e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—LEP—type 2 diabetes mellitus	4.12e-06	4.91e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—APOE—type 2 diabetes mellitus	4.12e-06	4.91e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CASP3—type 2 diabetes mellitus	4.1e-06	4.88e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—APOA1—type 2 diabetes mellitus	4.08e-06	4.85e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—IL6—type 2 diabetes mellitus	4.07e-06	4.85e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—INS—type 2 diabetes mellitus	4.06e-06	4.83e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.99e-06	4.75e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP2E1—type 2 diabetes mellitus	3.97e-06	4.73e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SLC2A1—type 2 diabetes mellitus	3.93e-06	4.68e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.92e-06	4.67e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.92e-06	4.67e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—EGFR—type 2 diabetes mellitus	3.9e-06	4.65e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	3.89e-06	4.63e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MMP9—type 2 diabetes mellitus	3.88e-06	4.61e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NFKB1—type 2 diabetes mellitus	3.83e-06	4.57e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PPARGC1A—type 2 diabetes mellitus	3.83e-06	4.56e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GNB3—type 2 diabetes mellitus	3.83e-06	4.56e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP3A4—type 2 diabetes mellitus	3.83e-06	4.56e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—HMOX1—type 2 diabetes mellitus	3.81e-06	4.54e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	3.81e-06	4.54e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SLC2A4—type 2 diabetes mellitus	3.77e-06	4.48e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GCG—type 2 diabetes mellitus	3.77e-06	4.48e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CAT—type 2 diabetes mellitus	3.76e-06	4.48e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—AKT1—type 2 diabetes mellitus	3.76e-06	4.48e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.73e-06	4.44e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IRS1—type 2 diabetes mellitus	3.68e-06	4.38e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—APOB—type 2 diabetes mellitus	3.65e-06	4.35e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SRC—type 2 diabetes mellitus	3.57e-06	4.25e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.56e-06	4.24e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.56e-06	4.24e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GSTM1—type 2 diabetes mellitus	3.55e-06	4.23e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—INS—type 2 diabetes mellitus	3.52e-06	4.19e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—LPL—type 2 diabetes mellitus	3.49e-06	4.15e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.48e-06	4.14e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.47e-06	4.13e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ADCY5—type 2 diabetes mellitus	3.41e-06	4.07e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.41e-06	4.06e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.41e-06	4.05e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GPX1—type 2 diabetes mellitus	3.4e-06	4.05e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	3.39e-06	4.04e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—RELA—type 2 diabetes mellitus	3.35e-06	3.99e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CD36—type 2 diabetes mellitus	3.31e-06	3.95e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PPP2CA—type 2 diabetes mellitus	3.27e-06	3.9e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GNB3—type 2 diabetes mellitus	3.25e-06	3.86e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PPARGC1A—type 2 diabetes mellitus	3.25e-06	3.86e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.24e-06	3.85e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—HMOX1—type 2 diabetes mellitus	3.23e-06	3.85e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.19e-06	3.8e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CAT—type 2 diabetes mellitus	3.19e-06	3.79e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—MTHFR—type 2 diabetes mellitus	3.14e-06	3.74e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.13e-06	3.73e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—APOB—type 2 diabetes mellitus	3.09e-06	3.68e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.09e-06	3.68e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.09e-06	3.68e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PPARA—type 2 diabetes mellitus	3.08e-06	3.67e-05	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	3.05e-06	3.63e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CASP3—type 2 diabetes mellitus	3.02e-06	3.6e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTM1—type 2 diabetes mellitus	3.01e-06	3.58e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL6—type 2 diabetes mellitus	3e-06	3.57e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—AGT—type 2 diabetes mellitus	2.98e-06	3.55e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—LPL—type 2 diabetes mellitus	2.95e-06	3.52e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CALM1—type 2 diabetes mellitus	2.93e-06	3.49e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—APOE—type 2 diabetes mellitus	2.92e-06	3.48e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—RELA—type 2 diabetes mellitus	2.91e-06	3.46e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ADCY5—type 2 diabetes mellitus	2.89e-06	3.44e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—APOA1—type 2 diabetes mellitus	2.89e-06	3.44e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GPX1—type 2 diabetes mellitus	2.88e-06	3.43e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.85e-06	3.4e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.82e-06	3.36e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CD36—type 2 diabetes mellitus	2.81e-06	3.34e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PPP2CA—type 2 diabetes mellitus	2.77e-06	3.3e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.77e-06	3.3e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—MTHFR—type 2 diabetes mellitus	2.66e-06	3.17e-05	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.65e-06	3.15e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SRC—type 2 diabetes mellitus	2.63e-06	3.13e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.62e-06	3.12e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PPARA—type 2 diabetes mellitus	2.61e-06	3.11e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.61e-06	3.1e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.56e-06	3.05e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PPARG—type 2 diabetes mellitus	2.55e-06	3.03e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—AGT—type 2 diabetes mellitus	2.53e-06	3.01e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—INS—type 2 diabetes mellitus	2.5e-06	2.97e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CALM1—type 2 diabetes mellitus	2.49e-06	2.96e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.48e-06	2.95e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—APOE—type 2 diabetes mellitus	2.48e-06	2.95e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.45e-06	2.92e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—APOA1—type 2 diabetes mellitus	2.45e-06	2.91e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL6—type 2 diabetes mellitus	2.41e-06	2.87e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.4e-06	2.86e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.35e-06	2.8e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.31e-06	2.75e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ALB—type 2 diabetes mellitus	2.29e-06	2.73e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SRC—type 2 diabetes mellitus	2.29e-06	2.72e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.23e-06	2.65e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.22e-06	2.64e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3R1—type 2 diabetes mellitus	2.19e-06	2.61e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NOS3—type 2 diabetes mellitus	2.19e-06	2.61e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PPARG—type 2 diabetes mellitus	2.16e-06	2.57e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—INS—type 2 diabetes mellitus	2.12e-06	2.52e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.04e-06	2.43e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PTGS2—type 2 diabetes mellitus	2e-06	2.38e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—EGFR—type 2 diabetes mellitus	2e-06	2.38e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ALB—type 2 diabetes mellitus	1.94e-06	2.31e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3R1—type 2 diabetes mellitus	1.86e-06	2.21e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NOS3—type 2 diabetes mellitus	1.86e-06	2.21e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL6—type 2 diabetes mellitus	1.77e-06	2.11e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PTGS2—type 2 diabetes mellitus	1.7e-06	2.02e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.64e-06	1.95e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL6—type 2 diabetes mellitus	1.54e-06	1.83e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.42e-06	1.69e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—AKT1—type 2 diabetes mellitus	1.01e-06	1.2e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—AKT1—type 2 diabetes mellitus	8.53e-07	1.02e-05	CbGpPWpGaD
